We want to know more about our readers. Tell us about yourself in
our short survey
for a chance to win a MacBook Air.
Research
Open Access
Apolipoprotein A5 and apolipoprotein C3 single nucleotide polymorphisms are correlated with an increased risk of coronary heart disease: a case–control and meta-analysis study
Triglycerides (TGs) are proatherogenic lipoproteins involving the risk of coronary heart disease (CHD), while apolipoprotein A5 (APOA5) and apolipoprotein C3 (APOC3) are main lipoproteins composing TG-rich lipoproteins. In this study, we aim to explore the correlation of CHD with APOA5 -1131 T > C and APOC3 -455 T > C single nucleotide polymorphisms (SNPs).
Methods
A sum of 210 CHD patients, hospitalized between Jan. 2013 and Mar. 2015 at China-Japan Union Hospital, Jilin University, were selected as our case group and 223 healthy individuals who had physical examination at same hospital at the same period were selected as control group. The frequency distribution of genotypes of APOA5 -1131 T > C and APOC3 -455 T > C SNPs were measured by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The Stata 12.0 software was utilized for statistical analyses.
Results
There was no significant difference on age and sex between case and control group (P > 0.05). History of smoking, drinking, hypertension and diabetes mellitus, body mass index and levels of TG and fasting blood sugar in case group were shown to be higher than control group (P < 0.05), while levels of total cholesterol, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol in case group were lower than control group (P < 0.05). Both CC and TC′ + CC frequencies of APOA5 -1131 T > C and APOC3 -455 T > C in case group were higher compared to control group (both P < 0.05). Additionally, T allele frequencies of the two SNPs in case group were lower than control group, while C allele in case group has higher frequencies compared to control group (both P < 0.05). The results of meta-analysis under allele and dominant models showed that APOA5 -1131 T > C and APOC3 -455 T > C SNPs are likely to increase the risk of CHD (both P < 0.05).
Conclusion
APOA5 -1131 T > C and APOC3 -455 T > C SNPs may play potent roles in the development and progression of CHD.
Coronary heart disease (CHD), also known as coronary atherosclerotic heart disease is a kind of thrombotic arterial disease, caused by hypoxia and myocardial ischemia owing to coronary atherosclerotic mediated vascular obstruction as well as coronary functional change [1, 2]. CHD has become one of leading diseases threatening human health and causing mortality, with an estimated 7.2 million individual worldwide die of this disease annually based on the World Health Organization [3]. In 2015, CHD alone caused approximately one of every seven deaths in the United States, and each year, there has emerged about 635,000 Americans who have a new coronary attack [4]. CHD is a complex multifactorial disorder and both non-genetic and genetic factors can contribute to the development and progression of this disease [5]. The non-genetic factors attributed to CHD has been clearly established, including type 2 diabetes, obesity, dyslipidemia, hypertension, low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and lifestyle, such as smoking, lack of exercise and high fat diet [6, 7]. Interestingly, there is an inverse relationship between triglyceride (TG) levels and HDL-C levels, and in metabolic syndrome, high LDL levels reduce the TG content of HDL, thus reducing the size of the HDL particle and making it more prone for renal clearance; besides, excess of TG in the HDL particle contribute to HDL dysfunction [8]. Circulating triglyceride-rich lipoproteins from hypertriglyceridemic subjects mediated endothelial inflammation and drive monocyte infiltration into the wall of arterial [9]. Although prime interest was devoted to LDL-C as proatherogenic, TG are considered in the last years to be also proatherogenic and some studies provide evidence for causal involvement of TG-mediated pathways in CHD and the concentration of it (both fasting and non-fasting) in prediction of future cardiovascular disease events [9–14].
Apolipoprotein A5 (APOA5) is a fourthly discovered member of the APOA4/APOC3/APOA1 apolipoprotein cluster and the human APOA5 gene is located at chromosome 11q23 [15]. APOA5 gene comprises four exons and encodes APOA5, a protein of 366 amino acids, which is an effective stimulator of lipoprotein lipase and can facilitate lipoprotein remnant clearance in a LDL receptor-dependent manner [16, 17]. It was reported that nucleotide sequence variations in the APOA5 gene have been correlated to high TG levels, exerting pleiotropic influences on different groups [18]. Apolipoprotein C3 (APOC3) is a significant component of TG-rich lipoproteins and a minor component of HDL [19]. APOC3 gene, also located in the chromosome 11q23, participates in transport and clearance of very-low-density lipoprotein (VLDL), chylomicron remnants, and HDL from the bloodstream [20]. APOC3 encodes a 79-amino-acid glycoprotein, which was produced largely in the liver interfering with receptor induced lipoprotein uptake and inhibiting the activation of lipoprotein lipase [21]. An increasing number of evidence suggested that APOA5 -1131 T > C and APOC3 -455 T > C single nucleotide polymorphisms (SNPs) contribute a substantial role in development of CHD owing to their correlation with increased plasma TGs, which has become the focus of oversea and domestic researchers [22, 23]. Nevertheless, there also emerged contradictory results on the role of APOA5 and APOC3 variants in CHD [24, 25]. In consideration of the controversial results from previous studies, we performed a case–control study to clearly address the correlation of CHD with APOA5 -1131 T > C and APOC3 -455 T > C, which was further confirmed by a following meta-analysis.
Materials and methods
Subjects
A total of 210 CHD patients (141 male and 69 female), hospitalized between Jan. 2013 and Mar. 2015 at China-Japan Union Hospital, Jilin University, were selected as our case group, among which 70 were acute myocardial infarction (MI), 109 were angina pectoris (27 stable, 82 unstable) and 31 were old MI. All CHD patients aged from 47 to 80 years, with mean age of 62.76 ± 9.98 years, and their diagnoses were based on American College of Cardiology/American Heart Association (2013) [26]. The diagnosis criteria were at least one with a diameter stenosis of ≥ 50 % in left main, left anterior descending, left circumflex and right coronary arteries, further examined by coronary arteriography and then evaluated through two interventional cardiologists. In addition, 223 healthy individuals (139 males and 84 females) who had physical examination at China-Japan Union Hospital, Jilin University at the same period were selected as control group, aged from 46 to 81 years (mean age: 62.44 ± 10.16 years). All subjects in control group had no positive sign, without history of CHD, cerebrovascular diseases or peripheral vascular diseases, and they showed normal in routine screening of blood and urine, chest X-ray, and liver and kidney function. Subjects included in our study have no blood relationship each other and we excluded subjects who had acute inflammation, rheumaimmune systemic diseases, malignant tumors, liver and renal diseases and thyroid disease (except hypertension and diabetes mellitus), and took lipid-lowering drugs in nearly four weeks. This study was authorized by the Ethical Committee of China-Japan Union Hospital, Jilin University, and all subjects included in our study provided written informed consent. All procedures in this study were in compliance with the Declaration of Helsinki [27].
Determination of biochemical indexes
Peripheral blood (5 ml) was collected from each subject on an empty stomach for 12 h. OLYMPUS AU640 Analyzer (YZB/JAP 0357) was employed to determine levels of TG, total cholesterol (TC), HDL-C, LDL-C and fasting blood sugar (FBS).
SNPs detection
APOA5 rs662799 and APOC3 rs2854116 SNPs were selected as our research targets. DNA extraction was undergone in the silicone membrane genomic DNA purification kit (Beijing SBS Genetech Co., Ltd.). The frequency distribution of allele and genotype of different SNPs in case and control group were measured by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). PCR primers were designed by Primer Premier 5.0 software (PREMIER Biosoft International, USA) and synthesized by Beijing Aoke Biotechnology Co., Ltd, and amplification site, primer sequence, fragment length, annealing temperature and number of cycles were presented in Table 1. For APOA5 -1131 T > C (rs662799), PCR amplification reaction was performed in a 20 μl reaction containing DNA 40 ng, 0.2 mol/L of each forward and reverse primer, 200 μmol/L dATP, dGTP, dCTP and dTTP, 0.5U Taq DNA polymerase and PCR buffer solution. PCR reaction was performed under the following conditions: predenaturation at 96 °C for 5 min with a total of 35 cycles, denaturation at 96 °C for 45 s, annealing at 59 °C for 30s and elongation at 72 °C for 45 s, with lastly elongation at 72 °C for 7 min. The PCR amplification products were allowed to digest with Mse I restriction enzyme (MBI Company) overnight, and digestion products were subjected to 10 % polyacrylamide gel electrophoresis. The gel was visualized by ethidium bromide staining and then photographed under ultraviolet (UV) light. With regard to APOC3 -455 T > C (rs2854116), PCR reaction mixture (50 μl) contains 10 × buffer 5 μl, dNTP 200 μmol/L, forward primer 25 pmol, reverse primer 25 pmol, genome DNA 50 ng and Taq DNA polymerase 0.5 U. After annealing at 60 °C for 30 cycles, 10 μl of PCR amplification products were digested at 37 °C by 8 U BseG I, from which 2 % gel electrophoresis was utilized to identify genotype, and the results were examined under UV light and then photographed. Gel electrophoresis of APOA5 -1131 T > C and APOC3 -455 T > C were shown in Fig. 1a ~ b.
Table 1
Primer sequencing of ApolipoproteinA5 (APOA5) -1131 T > C and apolipoproteinC3 (APOC3) -455 T > C single nucleotide polymorphisms (SNPs)
SNP
Primer
Fragment length (bp)
Annealing (°C)
Cycles
−1131 T > C (rs662799)
F: 5′-GATTGATTCAAGATGCATTTAGGAC-3′
188
59
35
R: 5′-CCCCAGGAACTGGAGCGAAATT-3′
−455 T > C (rs2854116)
F: 5′- GCACTCGCCTGCCTGGATT-3′
413
60
35
R: 5′- TGATGCCACGCTGCTGTCCC-3′
F forward, R reverse, SNP single nucleotide polymorphism
Fig. 1
Gel electrophoresis of apolipoprotein A5 (APOA5) -1131 T > C (rs662799) and apolipoprotein C3 (APOC3) -455 T > C (rs2854116) single nucleotide polymorphisms (SNPs) after enzyme digestion (a: -1131 T > C (rs662799) of APOA5; b: -455 T > C (rs2854116) of APOC3)
Statistical analysis
Data analyses of our case–control study were conducted using SPSS 18.0 software (IBM Corporation, Somers, NY, USA). Distributions of continuous variables were presented as means ± standard deviation, which was further examined with the use of t test, while quantitative data were shown as percent, which also further analyzed by chi-square test. In order to analyze deviation from the Hardy-Weinberg equilibrium, the observed and expected frequencies of genotype were compared with the utilization of chi-square test. Odds ratio (OR) with 95 % confidence interval (CI) were calculated to evaluate differences of genotype and allele frequencies between case and control groups. Two-tailed P values of < 0.05 were statistically significant. With regard to data analyses in the following meta-analysis, STATA 12.0 software (Stata Corp, College Station, TX, USA) was used. OR with 95 % CI in fixed-effect model or random-effect model, presented in forest plot, was calculated to assess the strength of the association of CHD with APOA5 -1131 T > C and APOC3 -455 T > C, whose overall estimates were examined by Z test [28].
Results
Clinical data and biochemical index
There was no significant difference on age and sex between case and control group (P > 0.05). History of smoking, drinking, hypertension and diabetes mellitus, and levels of TG and FBS, and body mass index (BMI) in case group were shown to be higher than control group (P < 0.05), while levels of TC, HDL-C and LDL-C in case group were lower than control group (P < 0.05) (Table 2).
Table 2
Comparison of clinical data and biochemical index between case and control groups (mean ± standard deviation)
Parameters
Case group (n = 210)
Control group (n = 223)
P
Mean age
62.76 ± 9.98
62.44 ± 10.16
0.7413
Sex (n, %)
M
141 (67.1 %)
139 (62.3 %)
0.2952
F
69 (32.9 %)
84 (37.7 %)
Smoking status (n, %)
Yes
113 (53.8 %)
61 (27.4 %)
< 0.0001
No
97 (46.2 %)
162 (72.6 %)
Drinking status (n, %)
Yes
128 (61.0 %)
93 (41.7 %)
< 0.0001
No
82 (39.0 %)
130 (58.3 %)
Hypertension status (n, %)
Yes
140 (66.7 %)
70 (31.4 %)
< 0.0001
No
70 (33.3 %)
153 (68.6 %)
Diabetes mellitus (n, %)
Yes
36 (17.1 %)
8 (3.6 %)
< 0.0001
No
174 (82.9 %)
215 (96.4 %)
TG (mmol/L)
2.41 ± 1.33
1.64 ± 1.00
< 0.0001
TC (mmol/L)
4.74 ± 0.98
5.05 ± 0.89
0.0006
HDL-C (mmol/L)
0.97 ± 0.32
1.33 ± 0.32
< 0.0001
LDL-C (mmol/L)
2.81 ± 0.76
3.07 ± 0.75
0.0004
FBS (mmol/L)
6.30 ± 1.60
5.08 ± 0.62
< 0.0001
BMI (kg/m2)
25.77 ± 3.21
24.29 ± 2.72
< 0.0001
M male, F female, TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, FBS fasting blood sugar, BMI body mass index
Distribution of APOA5 -1131 T > C and APOC3 -455 T > C SNPs
Distribution frequencies of genotypes of both APOA5 -1131 T > C and APOC3 -455 T > C SNPs complied with Hardy-Weinberg equilibrium in case and control groups (all P > 0.05), which indicated that this two SNPs were shown to be representative in this population. As shown in Table 3, both CC and TC′ + CC frequencies of APOA5 -1131 T > C and APOC3 -455 T > C in case group were higher compared to control group (both P < 0.05). Additionally, T allele frequencies of the two SNPs in case group were lower than control group, while C allele in case group has higher frequencies compared to control group (both P < 0.05).
Table 3
Distribution frequencies of genotypes in both apolipoproteinA5 (APOA5) -1131 T > C and apolipoproteinC3 (APOC3) -455 T > C single nucleotide polymorphisms (SNPs) between case and control groups
SNP
Control group (n = 223)
Case group (n = 210)
P
OR
95 % CI
−1131 T > C (rs662799)
TT
96 (43.0 %)
69 (32.9 %)
Ref
TC
107 (48.0 %)
101 (48.1 %)
0.194
1.313
0.870 ~ 1.983
CC
20 (9.0 %)
40 (19.0 %)
0.001
2.783
1.497 ~ 5.171
TT
96 (43.0 %)
69 (32.9 %)
Ref
TC + CC
127 (57.0 %)
141 (67.1 %)
0.029
1.545
1.044 ~ 2.285
T
299 (67.0 %)
239 (56.9 %)
Ref
C
147 (33.0 %)
181 (43.1 %)
0.002
1.54
1.169 ~ 2.031
−455 T > C (rs2854116)
TT
102 (45.7 %)
75 (35.7 %)
Ref
TC
101 (45.3 %)
97 (46.2 %)
0.199
1.306
0.868 ~ 1.965
CC
20 (9.0 %)
38 (18.1 %)
0.002
2.584
1.392 ~ 4.795
TT
102 (45.7 %)
75 (35.7 %)
Ref
TC + CC
121 (54.3 %)
135 (64.3 %)
0.034
1.517
1.031 ~ 2.233
T
305 (68.4 %)
247 (58.8 %)
Ref
C
141 (31.6 %)
173 (41.2 %)
0.003
1.515
1.147 ~ 2.002
SNP single nucleotide polymorphis
Meta-analysis results
Our meta-analysis enrolled a total of 11 case–control study [24, 29–38] including 4840 CHD patients and 4913 health individuals. The results, pooled from 9 studies reporting the association between CHD and APOA5 -1131 T > C, suggested that under allele model and dominant gene model -1131 T > C SNP is likely to increase the risk of CHD (allele model (C compared to T): OR = 1.65, 95 % CI = 1.53 ~ 1.79, P < 0.001, Fig. 2a; dominant model (TC+ CC compared to TT): OR = 1.55, 95 % CI = 1.17 ~ 2.06, P = 0.003, Fig. 2b). There were 3 studies that reported the association between CHD and APOC3 -455 T > C and meta-analysis results indicated that under allele model and dominant gene model -455 T > C SNP had potential to increase the risk of CHD (allele: OR = 0.64, 95 % CI = 0.51 ~ 0.80, P < 0.001, Fig. 3a; dominant: OR = 0.57, 95 % CI = 0.43 ~ 0.75, P < 0.001, Fig. 3b).
Fig. 2
Forest plots showing the correlations between apolipoprotein A5 (APOA5) -1131 T > C (rs662799) single nucleotide polymorphisms (SNPs) and coronary heart disease (a: allele model; b: dominant model)
Fig. 3
Forest plots showing the correlations between apolipoprotein C3 (APOC3) -455 T > C (rs2854116) single nucleotide polymorphisms (SNPs) and coronary heart disease (a: allele model; b: dominant model)
Discussion
The presented study evaluated the correlations of CHD with APOA5 -1131 T > C and APOC3 -455 T > C SNPs. Furthermore, in order to obtain a more conclusive and definitive estimation of the correlation of CHD with the two SNPs, our new case–control study combined with a meta-analysis pooled results from previously published studies were systematically carried out. The overall results of our study suggested that there was a strong link between the two SNPs, APOA5 -1131 T > C and APOC3 -455 T > C, with increased risk of CHD.
CHD, also known as coronary artery disease, is a multifactorial disorder, the risk of which was involved with some plasma lipids such as TC as well as TG, LDL-C, and HDL cholesterol (HDL-C), and lifestyles including smoking, alcohol consumption [39]. Additionally, both hypertension and diabetes mellitus were also involved in the development and progression of CHD [40]. In our study, we compared the clinical data and biochemical indexes of subjects between CHD patients and health individual, and the results demonstrated that CHD patients had longer history of smoking, drinking, hypertension along with diabetes mellitus, and lower levels of TC, HDL-C and LDL-C compared to health individuals.
One of our results in our study was that APOA5 -1131 T > C SNP is likely to increase the risk of CHD, which was further demonstrated by the following meta-analysis. APOA5, encoding apolipoprotein AV, is expressed in the liver and circulates on very low density lipoproteins, chylomicrons CM and HDL [41]. Apolipoprotein AV participates in the catabolism of triglyceride-rich particles by exerting the activation of lipoprotein lipase, leading to the promotion of TG hydrolysis [29]. The rare haplotype in vivo would result in the reduction of apolipoprotein AV synthesis, and thus there was less apolipoprotein AV that was available for incorporation into triglyceride-rich particles, with the consequence of less circulating apolipoprotein AV to promote the activation of lipoprotein lipase or to affect its receptor-mediated clearance, eventually developing atherosclerosis [10, 42]. In our study, CC and TC + CC frequencies of APOA5 -1131 T > C were higher compared to health individuals. Consist with our results, Sarwar et al. reported that the -1131 T > C (rs662799) promoter polymorphism of the APOA5 gene was related to higher VLDL concentration as well as smaller HDL particle size pathways by which triglyceride could exert influence on the risk of CHD [10].
Another results in the current study suggested that APOC3 -455 T > C had potential to increase the risk of CHD, which also further demonstrated by our meta-analysis. The metabolism of circulating particles rich in TGs is closely influenced by their content in APOC3 encoded by APOC3 gene, and it is a component that interferes with the lipoprotein lipase-triggered hydrolysis of these particles [21]. The APOC3 gene is transcriptionally down-regulated through insulin levels, and sequences in the promoter region with high adherence for the nuclear transcription factors inducing the insulin response are highly polymorphic [43]. Variants at positions −455 in APOC3 gene have been shown to have a decreased affinity for the nuclear transcription factors inducing the response, which is also relevant to a half of insulin-generated downregulation of APOC3 gene expression [44]. APOC3 is an important inhibitor of the lipolysis of triglyceride-rich lipoproteins via countering APOC2 activation of lipoprotein lipase [45]. Interestingly, Hypertriglyceridemia has been accepted by the National Cholesterol Education Program Adult Treatment Panel III as a potent risk factor for the development and progression of CHD [46].
In conclusion, our study demonstrated that APOA5 -1131 T > C and APOC3 -455 T > C SNPs may play potent roles in the development and progression of CHD. On a more practical ground, further researches with larger sample size are needed to examine whether incorporation of the APOA5 -1131 T > C and APOC3 -455 T > C SNPs into a general algorithm including genetic and metabolic variables will help further improving the identification of individuals at early risk of CHD.
Declarations
Acknowledgements
This study was funded by Jilin Youth Science Foundation (No: 20150520144JH). We would like to acknowledge the reviewers for their helpful comments on this paper.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ Affiliations
(1)
Department of Molecular Biology, College of Basic Medical Science, Jilin University
(2)
Department of Internal Medicine-Cardiovascular, the Fourth Affiliated Hospital of China Medical University
(3)
Department of Neurosurgery, FAW General Hospital, Jilin University
(4)
Department of Cardiology, China-Japan Union Hospital, Jilin University
Jiang G, Wang D, Li W, Pan Y, Zheng W, Zhang H, et al. Coronary heart disease mortality in China: age, gender, and urban–rural gaps during epidemiological transition. Rev Panam Salud Publica. 2012;31:317–24.View ArticlePubMedGoogle Scholar
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–322.View ArticlePubMedGoogle Scholar
Pranavchand R, Reddy BM. Current status of understanding of the genetic etiology of coronary heart disease. J Postgrad Med. 2013;59:30–41.View ArticlePubMedGoogle Scholar
Shen J, Zhang J, Wen J, Ming Q, Zhang J, Xu Y. Correlation of serum alanine aminotransferase and aspartate aminotransferase with coronary heart disease. Int J Clin Exp Med. 2015;8:4399–404.PubMed CentralPubMedGoogle Scholar
Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev. 2011;19:CD001561.Google Scholar
Santos-Gallego CG, Badimon JJ, Rosenson RS. Beginning to understand high-density lipoproteins. Endocrinol Metab Clin North Am. 2014;43:913–47.View ArticlePubMedGoogle Scholar
Rosenson RS, Davidson MH, Hirsh BJ, Kathiresan S, Gaudet D. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64:2525–40.View ArticlePubMedGoogle Scholar
Triglyceride Coronary Disease Genetics C, Emerging Risk Factors C, Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634–9.View ArticleGoogle Scholar
Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309–16.View ArticlePubMedGoogle Scholar
Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299–308.View ArticlePubMedGoogle Scholar
Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427–36.View ArticlePubMedGoogle Scholar
Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013;34:1826–33.View ArticlePubMedGoogle Scholar
Yin YW, Sun QQ, Wang PJ, Qiao L, Hu AM, Liu HL, et al. Genetic polymorphism of apolipoprotein A5 gene and susceptibility to type 2 diabetes mellitus: a meta-analysis of 15,137 subjects. PLoS One. 2014;9:e89167.PubMed CentralView ArticlePubMedGoogle Scholar
Garelnabi M, Lor K, Jin J, Chai F, Santanam N. The paradox of ApoA5 modulation of triglycerides: evidence from clinical and basic research. Clin Biochem. 2013;46:12–9.PubMed CentralView ArticlePubMedGoogle Scholar
van den Berg SA, Heemskerk MM, Geerling JJ, van Klinken JB, Schaap FG, Bijland S, et al. Apolipoprotein A5 deficiency aggravates high-fat diet-induced obesity due to impaired central regulation of food intake. FASEB J. 2013;27:3354–62.View ArticlePubMedGoogle Scholar
Soter MO, Gomes KB, Fernandes AP, Carvalho M, Pinheiro PS, Bosco AA, et al. −1131T>C and SW19 polymorphisms in APOA5 gene and lipid levels in type 2 diabetic patients. Mol Biol Rep. 2012;39:7541–8.View ArticlePubMedGoogle Scholar
Peter A, Kantartzis K, Machicao F, Machann J, Wagner S, Templin S, et al. Visceral obesity modulates the impact of apolipoprotein C3 gene variants on liver fat content. Int J Obes (Lond). 2012;36:774–82.View ArticleGoogle Scholar
Masebe T, Bessong PO, Ndip RN, Meyer D. Genetic variants of APOC3 promoter and HLA-B genes in an HIV infected cohort in northern South Africa: a pilot study. Int J Mol Sci. 2014;15:11403–15.PubMed CentralView ArticlePubMedGoogle Scholar
Jiang Y, Ma J, Li H, Liu Y, You C. Effect of apolipoprotein C3 genetic polymorphisms on serum lipid levels and the risk of intracerebral hemorrhage. Lipids Health Dis. 2015;14:48.PubMed CentralView ArticlePubMedGoogle Scholar
Zhang Z, Peng B, Gong RR, Gao LB, Du J, Fang DZ, et al. Apolipoprotein A5 polymorphisms and risk of coronary artery disease: a meta-analysis. Biosci Trends. 2011;5:165–72.View ArticlePubMedGoogle Scholar
Cui F, Li K, Li Y, Zhang X, An C. Apolipoprotein C3 genetic polymorphisms are associated with lipids and coronary artery disease in a Chinese population. Lipids Health Dis. 2014;13:170.PubMed CentralView ArticlePubMedGoogle Scholar
Martinelli N, Trabetti E, Bassi A, Girelli D, Friso S, Pizzolo F, et al. The −1131 T > C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study. Atherosclerosis. 2007;191:409–17.View ArticlePubMedGoogle Scholar
Prochaska CL, Picheth G, Anghebem-Oliveira MI, Costantini CO, de Souza EM, Pedrosa FO, et al. The polymorphisms -1131 T > C and the S19W of the APOA5 gene are not associated with coronary artery disease in a Brazilian population. Clin Chem Lab Med. 2010;48:419–22.View ArticlePubMedGoogle Scholar
Hemphill 3rd JC, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46:2032–60.View ArticlePubMedGoogle Scholar
PN M. World Medical Association publishes the Revised Declaration of Helsinki. Natl Med J India. 2014;27:56.Google Scholar
De Caterina R, Talmud PJ, Merlini PA, Foco L, Pastorino R, Altshuler D, et al. Strong association of the APOA5-1131 T > C gene variant and early-onset acute myocardial infarction. Atherosclerosis. 2011;214:397–403.View ArticlePubMedGoogle Scholar
Bhaskar S, Ganesan M, Chandak GR, Mani R, Idris MM, Khaja N, et al. Association of PON1 and APOA5 gene polymorphisms in a cohort of Indian patients having coronary artery disease with and without type 2 diabetes. Genet Test Mol Biomarkers. 2011;15:507–12.View ArticlePubMedGoogle Scholar
Jang Y, Paik JK, Hyun YJ, Chae JS, Kim JY, Choi JR, et al. The apolipoprotein A5–1131 T > C promoter polymorphism in Koreans: association with plasma APOA5 and serum triglyceride concentrations, LDL particle size and coronary artery disease. Clin Chim Acta. 2009;402:83–7.PubMed CentralView ArticlePubMedGoogle Scholar
Zhu MA, Zhou YL, Ding Y, Mao DY. The apolipoprotein A5–1131 T > C promoter polymorphism in patients with coronary artery disease. Chin J Gerontol. 2007;27:73–5.Google Scholar
Yu Y, Xue L, Zhao CY, Li JP, Huo Y. APOA5 gene polymorphisms in patients with coronary artery disease. J Peking Univ. 2007;39:576–80.Google Scholar
Li XP, Zhao SP, Nie S. Association of apolipoprotein A5-1131 T > C polymorphism and coronary heart disease. Chinese Circ J. 2007;22:4–8.Google Scholar
Hsu LA, Ko YL, Chang CJ, Hu CF, Wu S, Teng MS, et al. Genetic variations of apolipoprotein A5 gene is associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis. 2006;185:143–9.View ArticlePubMedGoogle Scholar
Olivieri O, Martinelli N, Sandri M, Bassi A, Guarini P, Trabetti E, et al. Apolipoprotein C-III, n-3 Polyunsaturated Fatty Acids, and “Insulin-Resistant” T− 455C APOC3 Gene Polymorphism in Heart Disease Patients: Example of Gene-Diet Interaction. Clin Chem. 2005;51:360–7.View ArticlePubMedGoogle Scholar
Bi N, Yan SK, Li GP, Yin ZN, Chen BS. A single nucleotide polymorphism -1131 T > C in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and alters triglyceride metabolism in Chinese. Mol Genet Metab. 2004;83:280–6.View ArticlePubMedGoogle Scholar
Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F, Girelli D, et al. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res. 2003;44:2374–81.View ArticlePubMedGoogle Scholar
Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345–52.PubMed CentralView ArticlePubMedGoogle Scholar
Akhabue E, Thiboutot J, Cheng JW, Vittorio TJ, Christodoulidis G, Grady KM, et al. New and emerging risk factors for coronary heart disease. Am J Med Sci. 2014;347:151–8.View ArticlePubMedGoogle Scholar
Palmen J, Smith AJ, Dorfmeister B, Putt W, Humphries SE, Talmud PJ. The functional interaction on in vitro gene expression of APOA5 SNPs, defining haplotype APOA52, and their paradoxical association with plasma triglyceride but not plasma apoAV levels. Biochim Biophys Acta. 2008;1782:447–52.View ArticlePubMedGoogle Scholar
Nilsson SK, Heeren J, Olivecrona G, Merkel M. Apolipoprotein A-V; a potent triglyceride reducer. Atherosclerosis. 2011;219:15–21.View ArticlePubMedGoogle Scholar
Khetarpal SA, Rader DJ. Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics. Arterioscler Thromb Vasc Biol. 2015;35:e3–9.View ArticlePubMedGoogle Scholar
Qamar A, Khetarpal SA, Khera AV, Qasim A, Rader DJ, Reilly MP. Plasma Apolipoprotein C-III Levels, Triglycerides, and Coronary Artery Calcification in Type 2 Diabetics. Arterioscler Thromb Vasc Bio. 2015;35:1880–8.View ArticleGoogle Scholar
Graham MJ, Lee RG, Bell 3rd TA, Fu W, Mullick AE, Alexander VJ, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112:1479–90.View ArticlePubMedGoogle Scholar
Harada LM, Carrilho AJ, Oliveira HC, Nakandakare ER, Quintao EC. Regulation of hepatic cholesterol metabolism in CETP/LDLr mice by cholesterol feeding and by drugs (cholestyramine and lovastatin) that lower plasma cholesterol. Clin Exp Pharmacol Physiol. 2006;33:1209–15.View ArticlePubMedGoogle Scholar
